Serum and ascites neutralizing antibodies in ovarian cancer patients treated with intraperitoneal adenoviral gene therapy.

Abstract

Human Gene TherapyVol. 13, No. 12 Brief ReportsSerum and Ascites Neutralizing Antibodies in Ovarian Cancer Patients Treated with Intraperitoneal Adenoviral Gene TherapyAkseli Hemminki, Minghui Wang, Renee A. Desmond, Theresa V. Strong, Ronald D. Alvarez, and David T. CurielAkseli HemminkiSearch for more papers by this author, Minghui WangSearch for more papers by this author, Renee A. DesmondSearch for more papers by this author, Theresa V. StrongSearch for more papers by this author, Ronald D. AlvarezSearch for more papers by this author, and David T. CurielSearch for more papers by this authorPublished Online:6 Jul 2004https://doi.org/10.1089/10430340260185139AboutSectionsPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail FiguresReferencesRelatedDetailsCited byM11: A Tropism-Modified Oncolytic Adenovirus Arming with a Tumor-Homing Peptide for Advanced Ovarian Cancer Therapies Fei Li, Yuan Yuan, Yun Dai, Teng Cheng, Heng Cao, Danmei Yan, Ying Li, Qian Sun, Xiaoyuan Huang, and Qinglei Gao16 March 2022 | Human Gene Therapy, Vol. 33, No. 5-6Understanding and addressing barriers to successful adenovirus-based virotherapy for ovarian cancer19 September 2020 | Cancer Gene Therapy, Vol. 28, No. 5Hitting the Target but Missing the Point: Recent Progress towards Adenovirus-Based Precision Virotherapies11 November 2020 | Cancers, Vol. 12, No. 11Ad5NULL-A20: A Tropism-Modified, αvβ6 Integrin-Selective Oncolytic Adenovirus for Epithelial Ovarian Cancer Therapies4 September 2018 | Clinical Cancer Research, Vol. 24, No. 17Oncolytic Adenovirus-Loaded Menstrual Blood Stem Cells Overcome the Blockade of Viral Activity Exerted by Ovarian Cancer AscitesMolecular Therapy - Oncolytics, Vol. 6Evaluation of CD46 re-targeted adenoviral vectors for clinical ovarian cancer intraperitoneal therapy27 May 2016 | Cancer Gene Therapy, Vol. 23, No. 7Predictive and Prognostic Clinical Variables in Cancer Patients Treated With Adenoviral Oncolytic ImmunotherapyMolecular Therapy, Vol. 24, No. 7Pseudotyped αvβ6 integrin-targeted adenovirus vectors for ovarian cancer therapies1 April 2016 | Oncotarget, Vol. 7, No. 19Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicineGynecologic Oncology, Vol. 141, No. 1Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic Applications24 November 2015 | Viruses, Vol. 7, No. 11Lymphokine‐activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascites18 September 2013 | International Journal of Cancer, Vol. 134, No. 5Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus12 May 2013 | Clinical Cancer Research, Vol. 19, No. 10Ad3-hTERT-E1A, a Fully Serotype 3 Oncolytic Adenovirus, in Patients With Chemotherapy Refractory CancerMolecular Therapy, Vol. 20, No. 9Role of cell surface molecules and autologous ascitic fluid in determining efficiency of adenoviral transduction of ovarian cancer cells11 June 2010 | Cancer Gene Therapy, Vol. 17, No. 10A Phase I Trial of Repeated Intrapleural Adenoviral-mediated Interferon-β Gene Transfer for Mesothelioma and Metastatic Pleural EffusionsMolecular Therapy, Vol. 18, No. 4E1B 55-kDa deleted, Ad5/F35 fiber chimeric adenovirus, a potential oncolytic agent for B-lymphocytic malignanciesThe Journal of Gene Medicine, Vol. 11, No. 6Extended release of adenovirus from silica implants in vitro and in vivo28 August 2008 | Gene Therapy, Vol. 16, No. 1Tat conjugation of adenovirus vector broadens tropism and enhances transduction efficiencyLife Sciences, Vol. 83, No. 21-22Changing the adenovirus fiber for retaining gene delivery efficacy in the presence of neutralizing antibodies10 April 2008 | Gene Therapy, Vol. 15, No. 12Significant alterations of biodistribution and immune responses in Balb/c mice administered with adenovirus targeted to CD40(+) cells29 November 2007 | Gene Therapy, Vol. 15, No. 4Oncolytic adenovirus Ad5/3-Δ24 and chemotherapy for treatment of orthotopic ovarian cancerGynecologic Oncology, Vol. 108, No. 1Identifying the safety profile of a novel infectivity-enhanced conditionally replicative adenovirus, Ad5-Δ24-RGD, in anticipation of a phase I trial for recurrent ovarian cancerAmerican Journal of Obstetrics and Gynecology, Vol. 196, No. 4Neutralized Adenovirus-Immune Complexes Can Mediate Effective Gene Transfer via an Fc Receptor-Dependent Infection PathwayJournal of Virology, Vol. 80, No. 20Transductional targeting of adenovirus vectors for gene therapy27 January 2006 | Cancer Gene Therapy, Vol. 13, No. 9Infectivity-Enhanced Adenoviruses Deliver Efficacy in Clinical Samples and Orthotopic Models of Disseminated Gastric Cancer17 May 2006 | Clinical Cancer Research, Vol. 12, No. 10Adenovirus-mediated intra-tumoral delivery of the human endostatin gene inhibits tumor growth in nasopharyngeal carcinoma14 November 2005 | International Journal of Cancer, Vol. 118, No. 8Adenoviruses with an RGD-4C modification of the fiber knob elicit a neutralizing antibody response but continue to allow enhanced gene deliveryGynecologic Oncology, Vol. 96, No. 2Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responsesMolecular Therapy, Vol. 11, No. 1Inter-patient variation in efficacy of five oncolytic adenovirus candidates for ovarian cancer therapy1 January 2004 | The Journal of Gene Medicine, Vol. 6, No. 12Gene transfer to cervical cancer with fiber-modified adenoviruses1 January 2004 | International Journal of Cancer, Vol. 111, No. 5Evaluation of a selectively oncolytic adenovirus for local and systemic treatment of cervical cancer1 January 2004 | International Journal of Cancer, Vol. 111, No. 2Modifying Adenoviral Vectors for Use as Gene-Based Cancer Vaccines Saroj K. Basak, Sylvia M. Kiertscher, Airi Harui, and Michael D. Roth30 July 2004 | Viral Immunology, Vol. 17, No. 2A cyclooxygenase-2 promoter-based conditionally replicating adenovirus with enhanced infectivity for treatment of ovarian adenocarcinoma4 March 2004 | Gene Therapy, Vol. 11, No. 6Modified Adenoviruses for Gene Therapy4 December 2009Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirusMolecular Therapy, Vol. 8, No. 3A canine conditionally replicating adenovirus for evaluating oncolytic virotherapy in a syngeneic animal modelMolecular Therapy, Vol. 7, No. 2 Volume 13Issue 12Aug 2002 To cite this article:Akseli Hemminki, Minghui Wang, Renee A. Desmond, Theresa V. Strong, Ronald D. Alvarez, and David T. Curiel.Serum and Ascites Neutralizing Antibodies in Ovarian Cancer Patients Treated with Intraperitoneal Adenoviral Gene Therapy.Human Gene Therapy.Aug 2002.1505-1514.http://doi.org/10.1089/10430340260185139Published in Volume: 13 Issue 12: July 6, 2004PDF download